

ZUCATOR M

Abbreviated Prescribing information for Zucator M (Remogliflozin Etabonate and Metformin Hydrochloride Tablets, 100, 500 mg and 100, 1000 mg) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Zucator M contains Remogliflozin Etabonate and Metformin Hydrochloride. Remogliflozin Etabonate inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Metformin Hydrochloride exerts its glucose-lowering effect by reduction of hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis; by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilization; and by delaying intestinal glucose absorption.

INDICATIONS: Zucator M is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients insufficiently controlled on their maximally tolerated dose of metformin alone, in patients already being treated with the combination of remogliflozin and metformin as separate tablets.

DOSAGE AND ADMINISTRATION: Zucator M should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. All patients should continue their diet with an adequate distribution of carbohydrate intake during the day. Dosing must be individualized for patients with impaired renal function.

WARNINGS & PRECAUTIONS: Renal impairment, lactic acidosis, diabetic ketoacidosis, administration of iodinated contrast agent, cardiac function, surgery, urinary tract infections, lower limb amputations, necrotising fasciitis of the perineum (Fournier's gangrene), elderly, urine laboratory assessments.

ADVERSE REACTIONS: Anaemia, vertigo, abdominal pain, constipation, diarrhoea, gastritis, asthma, fatigue, pyrexia, bacteriuria, genital infection fungal, vulvovaginal candidiasis, vulvovaginitis, blood bicarbonate abnormal, blood creatinine increased, blood/urine acid increased, glomerular filtration rate decreased, weight decreased, diabeticketoacidosis, dyslipidaemia, hypercholesterolaemia, hyperlactacidaemia, hypertriglyceridaemia, hypoglycaemia, lactic acidosis, polydipsia, pain in extremity, dizziness, headache, dysuria, ketonuria, pollakiuria, polyuria, renal failure, pruritus genital, vaginal discharge, vulvovaginal pruritus, hyperhidrosis, intertrigo, urticarial, orthostatic hypotension, lactic acidosis, decrease of vitamin b 12 absorption, erythema pruritus, urticaria.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

Torrent Pharmaceuticals Ltd.

IN/Zucator M 500, 1000/JAN-20/01/ABPI

(Additional information is available on request)